Rituximab immunotherapy in pemphigus: Therapeutic effects beyond B-cell depletion

Giovanna Zambruno, Luca Borradori

Research output: Contribution to journalArticlepeer-review


The anti-CD20 mAb rituximab, first approved for use in B-cell malignancies, is increasingly used to treat a variety of autoimmune diseases. Two studies in this issue investigate the effects of rituximab in pemphigus. Rituximab induces not only a depletion of all B cells and a decline of antidesmoglein autoantibodies but also a decrease in desmoglein-specific T cells. Furthermore, B-cell populations recovered after treatment were modified. These novel aspects may contribute to the clinical responses observed in patients.

Original languageEnglish
Pages (from-to)2745-2747
Number of pages3
JournalJournal of Investigative Dermatology
Issue number12
Publication statusPublished - Dec 2008

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology
  • Molecular Biology
  • Dermatology


Dive into the research topics of 'Rituximab immunotherapy in pemphigus: Therapeutic effects beyond B-cell depletion'. Together they form a unique fingerprint.

Cite this